Figure 1. Nuclear alterations in different forms of PCD.
The use of chromatin condensation as a criterion to distinguish apoptosis from apoptosis-like PCD has been inconsistent in the scientific literature, and the potential for overlapping definitions and errors is large. Electron-microscopic examples of classic apoptosis and apoptosis-like PCD (Leist and Jäättelä, 2001[Q1] ) or these schematic drawings might provide a general guideline. The control chromatin is speckled, showing areas of eu-and heterochromatin, and mostly one or several more condensed micronuclei (top middle). Caspase-dependent chromatin compaction and fragmentation to crescent-or spherical-shaped masses at the nuclear periphery is shown on the left. Caspase-independent chromatin margination triggered directly by microinjection of AIF or in a number of models of apoptosis-like death is shown at the bottom. Many intermediate forms and also transitions to necrosis are possible. Necrotic morphology is also observed in models where caspases are inhibited before apoptosis is completed (aborted apoptosis).
Death programs beyond caspases
In its classic form, apoptosis occurs almost exclusively when caspases, particularly caspase-3, are activated (Woo et al., 1998; Susin et al., 2000) . The unexpected ability of certain cells to survive the activation of proapoptotic caspases (Lacana et al., 1997; Wright et al., 1997; Jäättelä et al., 1998; De Maria et al., 1999; Zeuner et al., 1999; Harvey et al., 2000; Foghsgaard et al., 2001; Hoeppner et al., 2001; Los et al., 2001; Reddien et al., 2001) demonstrates, however, the remarkable plasticity of the cellular death program, and argues against the idea that caspases alone are sufficient for the induction of mammalian PCD. Furthermore, recent evidence indicates a diversification of the apoptosis program in higher eukaryotes with respect to the necessity and role of caspases. Signals emanating from the established key players of apoptosis, including death receptors and caspases themselves, may result in necrosis-like PCD (Leist et al., 1997; Vercammen et al., 1998a,b; Khwaja and Tatton, 1999; Leist et al., 1999; Holler et al., 2000) , and apoptosis-like PCD characterized by chromatin condensation and phosphatidylserine exposure is not necessarily accompanied by effector caspase activation (Berndt et al., 1998; Lavoie et al., 1998; Monney et al., 1998; Mathiasen et al., 1999; Roberts et al., 1999; Nylandsted et al., 2000[Q2] ; Gingras et al., 2002) . Other important apoptosis hallmarks, such as detachment, shrinkage, and zeiosis, can also be present in cells dying in a caspase-independent manner (McCarthy et al., 1997; Berndt et al., 1998; Nylandsted et al., 2000[Q2] ; Foghsgaard et al., 2001; Joza et al., 2001; Gingras et al., 2002) .
Contrary to earlier expectations, the inhibition of caspase activation does not necessarily protect against cell death stimuli. Instead, it may reveal, or even enhance, underlying caspase-independent death programs. These programs may take the form of apoptosis-like (Deas et al., 1998; Luschen et al., 2000; Foghsgaard et al., 2001; Joza et al., 2001; Volbracht et al., 2001[Q3] ), or necrosis-like (Xiang et al., 1996; Leist et al., 1997; McCarthy et al., 1997; Vercammen et al., 1998a,b; Chautan et al., 1999; Khwaja and Tatton, 1999; Xue et al., 1999; Holler et al., 2000; Matsumura et al., 2000) PCD. In many experimental apoptosis models, including those triggered by death receptors (Vercammen et al., 1998a,b; Holler et al., 2000; Matsumura et al., 2000) , cancer drugs (Amarante-Mendes et al., 1998) , growthfactor deprivation (Xue et al., 1999) , staurosporine (Deas et al., 1998) , anti-CD2 (Deas et al., 1998) , oncogenes (McCarthy et al., 1997) , colchicine (Volbracht et al., 2001[Q3] ), GD3 (Simon et al., 2001) , or expression of Bax-related proteins (Xiang et al., 1996; McCarthy et al., 1997) , the existence of backup death pathways has been uncovered following inhibition of caspase activity by pharmaceutical pancaspase inhibitors. However, several lines of evidence support the relevance of such 'second-line' mechanisms also for normal physiology and pathology. In addition to pharmacologic inhibitors, caspase pathways can be inactivated by other factors such as mutations (Chautan et al., 1999) , energy depletion (Leist et al., 1997) , nitrative/oxidative stress (Leist et al., 1999) , other proteases that are activated simultaneously (Chua et al., 2000; Lankiewicz et al., 2000; Reimertz et al., 2001) , members of the 'inhibitor of apoptosis protein' (IAP) family (Jäättelä, 1999; , defective release of Smac/Diablo (Deng et al., 2002) , or an array of viral proteins that can silence caspases . Thus, it is not surprising that the list of model systems where PCD is not accompanied by the effector caspase activation is growing ( Table 1) . This is especially evident in cancer cells, which often harbor defects in classic apoptosis pathways (Jäättelä, 1999) .
Upon caspase inhibition, the alternative death pathways surface also in vivo. They are involved in processes such as the negative selection of lymphocytes (Smith et al., 1996; Doerfler et al., 2000) , cavitation of embryoid bodies (Joza et al., 2001) , embryonic removal of interdigital webs (Chautan et al., 1999) , tumor necrosis factor (TNF)-mediated liver injury (Kunstle et al., 1999) , and the death of chondrocytes controlling the longitudinal growth of bones (Roach and Clarke, 2000) . These examples may represent just the tip of the iceberg with regard to the complexity of death signaling in vivo. And the overlapping death pathways initiated by a single stimulus seem rather to be the rule than the exception (Holler et al., 2000; Charette et al., 2001; Joza et al., 2001) . The examination of potential crossovers of death pathways that lead eventually to different phenotypic outcomes may offer a chance to understand which events do determine commitment to death, and which ones are instead involved in upstream signaling or downstream execution.
Signaling in caspase-independent PCD
Several molecular mediators of classic caspase-mediated apoptosis pathways have been characterized during the last decade (Mattson, 2000; Kaufmann and Hengartner, 2001) , whereas the description of most alternative death routines has remained limited to the phenomenological level. But recent mechanistic findings have opened a new era in this field. Like classic apoptosis, alternative death programs can be mediated by proteases and switched on by mitochondrial alterations or death receptors.
Noncaspase proteases as mediators of PCD
The most extensive evidence linking noncaspase proteases with PCD originates from studies of calpains; cathepsins B, D, and L; and granzymes A and B (Kitanaka and Kuchino, 1999; Johnson, 2000; Leist and Jäättelä, 2001[Q1] ). These proteases cooperate often with caspases in classic apoptosis, but recent data suggest that they can also trigger PCD and bring about many of the morphologic changes characteristic of apoptosis in a caspase-independent manner (Johnson, 2000; Wang, 2000; Leist and Jäättelä, 2001 [Q1]) [Q4]( Table 2 ). As noncaspase proteases have only recently attracted broader interest among cell-death researchers, this list is likely to present only a fraction of all PCD-mediating proteases.
Cathepsins
The cathepsin protease family comprises cysteine, aspartate, and serine proteases (Johnson, 2000; Turk et al., 2001) . So far, the cysteine cathepsins B and L and the aspartate cathepsin D have been most clearly linked to PCD. Most cathepsins mature in the endosomal-lysosomal compartment. They can be activated by autoproteolysis in acidic pH or proteolysis by other proteases (for example, cathepsin D can activate cathepsins B and L). Furthermore, ceramide specifically binds to and promotes the proteolytic activation of cathepsin D, possibly linking sphingomylinase-mediated ceramide production and cathepsins to a common PCD pathway (Heinrich et al., 1999) . Until recently, the function of cathepsins was presumed to be limited to the disposal of proteins in the lysosomal compartment and degradation of extracellular matrix once secreted. During the past few years, however, many of them have been assigned specific functions, as, for example, in bone remodeling, hair follicle morphogenesis, antigen presentation, and PCD (Reinheckel et al., 2001; Turk et al., 2001) . Genetic evidence for the role of cysteine cathepsins in PCD is provided by studies showing resistance to TNF-induced liver apoptosis in mice that lack cathepsin B (Guicciardi et al., 2001) , and massive PCD in the brains of mice that lack the cysteine cathepsin inhibitor, cystatin B (Pennacchio et al., 1998) . Cathepsins participate in both caspase-dependent and -independent PCD induced by a variety of stimuli, including death receptors, camptothecin, B-cell receptors, bile salt, oxidants, and retinoids (Roberts et al., 1997 (Roberts et al., , 1999 van Eijk and de Groot, 1999; Guicciardi et al., 2000; Foghsgaard et al., 2001; Katz et al., 2001; Roberg, 2001; Zang et al., 2001) . Cathepsins translocate from lysosomes to the cytosol and/or nucleus before the appearance of gross morphologic changes indicative of PCD. Notably, the inhibition of cathepsin activity protects cells from PCD without preventing the release of cathepsins from the lysosomes (Foghsgaard et al., 2001) . These data indicate that the release of cathepsins is not merely a sign of final organelle disintegration in the dying cell, and suggest that cathepsins have to escape the lysosomal compartment to trigger PCD. The latter hypothesis is further supported by the data showing that microinjection of cathepsin D (K. Roberg, personal communication), as well as limited disruption of lysosomes, triggers apoptosis dependent on cathepsin activity (Kagedal et al., 2001) . It should also be noted that in some cells cathepsins may be pivotal for survival, as the cysteine cathepsin inhibitor, CATI-1, kills leukemia and lymphoma cells (Zhu and Uckun, 2000) .
Calpains
Calpains are cysteine proteases that reside in the cytosol in an inactive zymogen form (Johnson, 2000; Wang, 2000) . Two forms of calpains, µ-calpain and m-calpain, are ubiquitously expressed in human cells and have been linked to differentiation and PCD. The active forms of the enzymes consist of a variable large subunit (80 kDa) and a common small subunit (30 kDa Table 2 ) that increase the [Ca 2+ ] i and they can participate in PCD signaling upstream or downstream of caspases (Leist et al., 1998; Waterhouse et al., 1998; Nakagawa and Yuan, 2000; Choi et al., 2001; Varghese et al., 2001) . Furthermore, calpains can mediate apoptosis-like PCD, even in the absence of caspase activation (Mathiasen et al., 1999; I. S. Mathiasen and M. Jäättelä, unpublished) . For example, EB1089/seocalcitol, a vitamin D analog currently on phase III clinical trials for the treatment of cancer, induces calcium-and calpain-dependent apoptosis-like PCD in breast cancer cells without triggering detectable caspase activation.
Serine proteases
The most prominent components of cytotoxic granules of cytotoxic lymphocytes are the pore-forming protein, perforin, and the serine proteases, granzyme A and granzyme B (Johnson, 2000; Trapani et al., 2000) . Upon activation, cytotoxic lymphocytes release their granular contents. Subsequently, target cells take up granzymes by receptor-mediated endocytosis and subsequent perforin-mediated release from endosomes into the cytosol or by diffusion via perforin-generated pores in the plasma membrane. Studies employing mice lacking either granzyme A or B have demonstrated that granzyme B is required for the granule-induced rapid caspase-mediated apoptosis (Johnson, 2000) . Granzyme B cleaves its substrates after aspartate residues and can thus directly activate caspases. However, in the presence of caspase inhibitors, granzyme B triggers a slower necrosis-like PCD (Talanian et al., 1997) . Granzyme A is a trypsin-like protease that cleaves its substrates after lysine or arginine residues. Death induced by granzyme A is associated with DNA single-strand breaks created by a granzyme A-activated DNase (Beresford et al., 2001) .
Other serine proteases that have been associated with cell death include apoptotic protease 24 (AP24), which mediates DNA fragmentation in TNF-, UV light-, and chemotherapy-induced PCD of some cancer cells (Wright et al., 1997; 1998) , and the recently identified omi/htra2 (Suzuki et al., 2001) , which is released from mitochondria into the cytosol during apoptosis, and can mediate caspase-independent PCD dependent on its serine protease activity and/or contribute to the caspase activation by counteracting members of IAP family. A family of protease inhibitors called serpins inhibits the activity of serine proteases. Interestingly, the serine-protease-mediated inactivation of a serpin, leukocyte elastase inhibitor (LEI), transforms LEI into an endonuclease, L-DNase II (Torriglia et al., 1998) . LDnase II translocates to the nucleus in various PCD models; it can induce pyknosis and DNA degradation in vitro. Thus, the transformation of LEI to L-DNase II may act as an important switch of protease and nuclease pathways during caspase-independent PCD.
The definition of the role of the individual proteases in the complex process of PCD still requires much careful work. The dependence on certain proteases may be extremely cell-type and stimulus specific, and may depend on the relative expressions, activations, and inactivations of proteases and protease inhibitors ( Table 2 and Figure 2 ). Genetic approaches need to be combined with meticulous pharmacologic titration of inhibitors (Foghsgaard et al., 2001) , since it turns out that pancaspase inhibitors, as well as many active site inhibitors of other proteases, are highly unspecific at concentrations widely used to test their role in PCD (Schotte et al., 1998; Waterhouse et al., 1998; Johnson, 2000; Foghsgaard et al., 2001 ).
Death receptors as triggers of alternative PCD
The best-studied members of the death-receptor family are TNF receptor 1 (TNF-R1), Fas (also known as CD95 or Apo-1), and the receptors for TNF-related apoptosis-inducing ligand (TRAIL). Whereas it has long been known that TNF-induced death can take the shape of either apoptosis or necrosis (Laster et al., 1988) , the ability of the Fas ligand (FasL) and TRAIL to induce necrosis-like PCD has been Frequently, an inactive or weakly active zymogen (preprotease) is activated by the cleaving of a prodomain (PD) (the first level of protease family interaction; examples shown in italics). Intracellular protease activity is prevented by specific antiproteases (AP), and ultimate activation requires inactivation of AP (often by proteolysis, the second level of protease family interaction). Further proteolysis can lead to inactivation of the active protease and eventually degradation (the third level of protease family interaction). The balance of all players in this circle determines which proteases dominate the death process. Pharmacologic inhibition of one protease easily shifts the balance to another pathway. described only recently (Leist et al., 1997; Kawahara et al., 1998; Vercammen et al., 1998a,b; Leist et al., 1999; Holler et al., 2000) . In activated primary T cells, this caspase-independent necrosis-like PCD seems, at least in some cases, to be the dominant mode of death (Holler et al., 2000) . This may explain why inhibition of caspase activity in mouse T cells in vivo does not induce the lymphadenopathy and/or autoimmune disease usually manifested in mice with inactivating mutations in Fas or Fas ligand (Smith et al., 1996) .
Except for the dependence on reactive oxygen species (ROS) and, in some cases, serine protease activity, necrotic signaling pathways have remained ambiguous until recently (Denecker et al., 2001 ). Novel data demonstrate now that TNF, FasL, and TRAIL can trigger caspase-8-independent necrosis-like PCD that is dependent on the Fas-associated death domain (FADD) protein and the kinase activity of the receptor-interacting protein (RIP) (Holler et al., 2000) . The dependence of RIPmediated necrotic PCD on proteases remains to be studied. Interestingly, some TNF-resistant cells are sensitized to TNF-induced necrosis-like PCD upon inhibition of caspases, suggesting that caspases act as survival factors that directly inhibit the TNF-induced necrotic pathway (Khwaja and Tatton, 1999) . Death receptors can also trigger caspase-independent apoptosis-like PCD. In immortalized epithelial cells, activated Fas has been reported to recruit Daxx from the nucleus to the receptor complex, and to trigger its binding with apoptosis signal-regulating kinase 1 (Ask1) (Charette et al., 2000; Ko et al., 2001) . Others have, however, have failed to detect Daxx in the cytosol and have suggested that Daxx enhances Fas-induced caspase-dependent death from its nuclear localization (Torii et al., 1999) . Thus, Daxx may stimulate Fas-induced death by two independent mechanisms, the caspase-independent pathway being evident only when caspase activation is defective (Charette et al., 2000) and enough Ask1 is available (Ko et al., 2001) . In addition to a caspase-dependent proapoptotic function that depends on its kinase activity, Ask1 possesses a caspase-independent killing function that is independent of its kinase activity and is activated by interaction with Daxx (Charette et al., 2001 ). Ask1 has also been found to be essential for TNF-triggered apoptosis of primary fibroblasts, but its activation by TNF appears to require ROS (Tobiume et al., 2001) instead of Daxx (Yang et al., 1997) . In TNF-treated fibrosarcoma cells cysteine cathepsins act as dominant execution proteases and bring about apoptosis-like morphologic changes (Foghsgaard et al., 2001) . Whether Ask1 and cathepsins act on the same signaling pathway is as yet unknown.
The picture described above suggests a complexity of death-receptor-induced apoptotic and necrotic signaling networks that far exceeds that of the simple linear pathway originally suggested by the discovery of the receptor-triggered caspase cascade (Figure 3 ).
Mitochondrial control of caspase-independent PCD
Analogous to classic apoptosis, mitochondrial membrane permeabilization (MMP) controlled by Bcl-2 family proteins resides at the heart of several alternative death pathways. The prevailing theory suggests that 'multidomain' proapoptotic Bcl-2 family members (such as Bax and Bak) are the actual pore-forming effector molecules required for MMP (Cheng et al., 2001; Wei et al., 2001 ). Bax and/or Bak can be activated transcriptionally or by conformational change induced by cleavage or binding to an activated BH3-only Bcl-2 family member (Figure 4) . Antiapoptotic Bcl-2 proteins (such as Bcl-2 and Bcl-X L ) oppose the MMP, probably by heterodimerization with Bax-like proteins, whereas 'BH3-only' Bcl-2 family members either oppose the inhibitory effect of Bcl-2-like proteins (Bad, Bim, Noxa, PUMA, etc.) or activate Bax-like proteins by direct binding (truncated Bid). The pathways upstream of MMP are numerous and with a few exceptions caspaseindependent (Heibein et al., 2000; Choi et al., 2001; Ferri and Kroemer, 2001; Kaufmann and Hengartner, 2001; Stoka et al., 2001) (Figure 4) .
MMP does not necessarily result in an irreversible mitochondrial dysfunction and cell death. Initially, the pore-forming proapoptotic Bcl-2 family members Bax and Bak induce only outer membrane permeability but leave intact inner membrane energization, protein import function, and the ultrastructure of mitochon- The final execution of the death -that is, phosphatidylserine exposure, chromatin condensation, and loss of viability -is brought about by effector caspases, the serine protease AP24, or cathepsin B in a cell-type-specific manner. dria (Von Ahsen et al., 2000b) . Recent data indicate that MMP prompts several caspase-dependent and -independent death pathways (Leist and Jäättelä, 2001 [Q1]) ( Figure 5 ). The apoptosome-caspase pathway leading to classic apoptosis is initiated by the MMP-dependent release of cytochrome c from the mitochondrial intermembrane space. Together with other essential factors (such as ATP), it triggers assembly of the apoptosome complex, which forms the template for efficient caspase processing. As a further safeguard mechanism, caspase-inhibitory factors (IAPs and XIAP) have to be removed by additional proteins (DIABLO/SMAC or Omi/HtrA2) released from mitochondria before the execution caspases can become fully active and produce the typically apoptotic morphology Kaufmann and Hengartner, 2001) .
The second mitochondrial death pathway leads to necrotic PCD, without necessarily activating caspases. A prominent example is TNF-induced necrosis-like PCD mediated by mitochondria-derived ROS (Schulze-Osthoff et al., 1992) . Intracellular control of this pathway is indicated by its susceptibility to attenuation by antioxidants (Vercammen et al., 1998a,b; Schulze-Osthoff et al., 1992) . A third distinct pathway from mitochondria is the release of the apoptosisinducing factor (AIF) from the intermembrane space (Susin et al., 1999; Suter et al., 2000; Braun et al., 2001) . Recent genetic evidence indicates that this factor controls PCD in early development; that is, all the hallmarks of early morphogenetic death, including cytochrome c release, are prevented by deletion of AIF (Joza et al., 2001) . AIF induces caspase-independent formation of large (50-bp) chromatin fragments, whereas oligonucleosomal DNA fragments are generated only when caspase-activated DNase (CAD) is activated (Susin et al., 1999; . This biochemical difference is reflected by slight morphologic differences in the shape of the condensed chromatin (Figure 1) .
Finally, endonuclease G or a serine protease, Omi/htra2, released from mitochondria during PCD can contribute to the caspase-independent death signaling downstream of MMP (Li et al., 2001; Suzuki et al., 2001) . Extramitochondrial expression of Omi/htra2 induces caspase-independent PCD, and endonuclease G causes caspase-independent DNA fragmentation in isolated nuclei. However, direct evidence connecting endonuclease G and PCD-associated DNA fragmentation in mammalian cells is still lacking.
Often, more than one pathway seems to be activated simultaneously (Jäättelä et al., 1998; Susin et al., 1999; Mattson, 2000; Suter et al., 2000) . The cell fate and death mechanism are then determined by the relative speed of each process in a given model system, and by the antagonists of the individual pathways differentially expressed in different cell types. AIF, caspases, and ROS can feed back on Mitochondrial damage leads to the release of numerous mitochondrial proteins that may trigger the execution of PCD. Cytochrome c release triggers caspase activation and classic apoptosis. Smac/Diablo and Omi/htra2 assist cytochrome c-induced caspase activation by counteracting IAPs. AIF triggers a caspase-independent death pathway, culminating in the DNA fragmentation and stage 1 chromatin condensation characteristic of apoptosis-like PCD. Endonuclease G cleaves DNA and induces stage 1 chromatin condensation. The serine protease activity of Omi/htra2 mediates caspase-independent cellular rounding and shrinkage without changes in the nuclear morphology. Ca 2+ and ROS can lead to severe mitochondrial dysfunction and necrosis-like PCD. All these mitochondrial events are at least partially inhibited by Bcl-2. mitochondria, causing enough structural and functional damage to trigger the release of other death factors, independently of the upstream signals (Nicotera et al., 1999; Susin et al., 1999; Mattson, 2000; .
Defects in any step of the cytochrome c or AIF pathways can switch apoptosis or apoptosis-like PCD to death with a necrotic morphology (Leist et al., 1997; McCarthy et al., 1997; Daugas et al., 2000) . This death would still fulfill the criteria of PCD, as it is blocked by the antiapoptotic oncogenes Bcl-2 or Bcr-Abl (Amarante- Mendes et al., 1998; Daugas et al., 2000; Single et al., 2001) or by the deletion of proapoptotic Bax (Miller et al., 1997) . Moreover, caspase inhibition changes the mode of death, but not its extent, once the signal has arrived at mitochondria (Xiang et al., 1996; Hirsch et al., 1997; Leist et al., 1997; McCarthy et al., 1997; Miller et al., 1997; Amarante-Mendes et al., 1998; Nicotera et al., 1999; Daugas et al., 2000) . Thus, it seems that in many models of cell death the master controllers of PCD operate at the mitochondrial level, while the decision on the form of death is taken at the level of caspase activation (Nicotera et al., 1999) .
There are, however, certain cases where Bcl-2 expression is not protective, and where mitochondria may not have a regulatory role (Chi et al., 1999; Schierle et al., 1999; Elliott et al., 2000; Finn et al., 2000; Nylandsted et al., 2000[Q2] ; Sperandio et al., 2000) . Although the alternative control mechanisms are not well characterized, emerging candidates include different chaperone systems, such as heat-shock proteins (Jäättelä et al., 1998; Charette et al., 2000; Nylandsted et al., 2000[Q2] ) or ORP150 (Tamatani et al., 2001) . Organelles that have not received much attention until recently, such as the endoplasmic reticulum and lysosomes, might also take an essential role in the control of death (Mattson, 2000; Ferri and Kroemer, 2001; Leist and Jäättelä, 2001 [Q1]) (Figure 4) .
The significance of the program: removal of corpses
Death is not the only important endpoint of PCD. A much less complicated machinery would be sufficient to permeabilize the plasma membrane. The classic apoptosis program is, in fact, optimized to ensure that signals for phagocytosis are displayed well before cellular constituents might be released (Savill and Fadok, 2000; . In extreme cases, there is even a feedback control of phagocytosis on the death program itself to ensure that death occurs only when phagocytosis has been initiated (Hoeppner et al., 2001; Reddien et al., 2001) . Does this also apply to caspase-independent programs? A dominant uptake signal in mammalian cells is the translocation of phosphatidylserine to the outer leaflet of the plasma membrane. Also this 'eat-me' indicator is uncoupled from caspase activation in many model systems (Berndt et al., 1998; Mateo et al., 1999; Fröhlich and Madeo, 2000; Hirt et al., 2000; Foghsgaard et al., 2001) , and nonapoptotically dying eukaryotic cells can be efficiently phagocytized (Hirt et al., 2000) . Mechanisms that can lead to the translocation of phosphatidylserine and phagocytosis in cells undergoing caspase-independent death include disturbances of cellular calcium homeostasis and protein kinase C activation (Hirt et al., 2000; Volbracht et al., 2001[Q3] ). Noncaspase cysteine proteases might be involved not only in the alternative death execution, but also in alternative phagocytosis signal pathways. For instance, cathepsin B activity is required for the translocation of phosphatidylserine in TNF-challenged tumor cells (Foghsgaard et al., 2001) , and, in the apoptosislike death of platelets, calpain inhibitors selectively block phagocytosis signals (Wolf et al., 1999) . Finally, genetic analysis in C. elegans has shown that the same phagocytosis-recognition molecules are involved in removing corpses produced by caspase-dependent apoptosis and caspase-independent necrosis (Chung et al., 2000) .
Complex control of tumor cell death
Paradoxically, the cell proliferation induced by enhanced activity of oncoproteins (such as Myc, E1A, E2F, and CDC25) or inactivation of tumor suppressor proteins (retinoblastoma protein, for example) is often associated with caspase activation and accelerated apoptosis (Schmitt and Lowe, 1999) . The coupling of cell division to cell death has thus been proposed to act as a barrier that must be circumvented for cancer to occur (Jäättelä, 1999; Schmitt and Lowe, 1999) . Indeed, high expression of the antiapoptotic proteins (Bcl-2, Bcl-x L , survivin, and Bcr-Abl) and/or inactivation of the proapoptoic tumor-suppressor proteins (p53, p19 ARF , and PTEN) controlling caspase-dependent apoptosis pathways are often seen in human tumors (Jäättelä, 1999; Schmitt and Lowe, 1999) .
Alternative death pathways in cancer
Despite showing severe defects in classic apoptosis pathways, cancer cells have not lost the ability to commit suicide. On the contrary, spontaneous apoptosis is common in aggressive tumors, and most of them respond to therapy (Kerr et al., 1994) . One explanation may be that defects in the signaling pathways leading to caspase activation may still allow caspase-independent death pathways to execute tumor cell death.
The alternative death pathways may also be enhanced by transformation ( Figure 6 ). For example, oncogenic Ras can induce caspase-and Bcl-2-independent autophagic death (Chi et al., 1999) , and tumor-associated Src family kinases are involved in caspase-independent cytoplasmic execution of apoptotic programs induced by the adenovirus protein E4orf4 (Lavoie et al., 2000; Gingras et al., 2002) . Furthermore, a transformation-associated caspase-, p53-, and Bcl-2-independent, apoptosis-like death program can be activated in tumor cell lines of different origins by depletion of a 70-kDa heat-shock protein (Hsp70) (Nylandsted et al., 2000a,b) . This death is preceded by a translocation of active cysteine cathepsins from lysosomes to cytosol, and inhibitors of their activity partially protect against death. Interestingly, cysteine cathepsins, as well as other noncaspase proteases, are highly expressed in aggressive tumors (Duffy, 1996) .Therefore, expression of protease inhibitors may increase a cancer cell's chances of survival by impairing alternative death routes (Alexander et al., 1996; Foghsgaard et al., 2001; Leist and Jäättelä, 2001[Q1] ).
Alternative death pathways can also function at an initial stage of tumorigenesis to limit tumor formation. Bin1, a tumor-suppressor protein that is often missing or functionally inactivated in human cancer, can activate a caspase-independent apoptosis-like death process that is blocked by a serine protease inhibitor or the simian virus large T antigen, but not by overexpression of Bcl-2 or inactivation of p53 (Elliott et al., 2000) . Similarly, the promyelocytic leukemia PML/RARα oncoprotein also inhibits caspase-independent PCD induced by the PML tumor-suppressor protein (Quignon et al., 1998) . Interestingly, the cytoplasmic apoptotic features induced by ectopic expression of PML can even be enhanced by pancaspase inhibitors (Quignon et al., 1998) . It should, however, be noted that PML/RARA can also interfere with caspase activation in some death models (Wang, Z.G. et al., 1998) .
Designing new therapies based on alternative PCD pathways
Experimental gene-therapy approaches point to alternative death pathways as promising targets for tumor therapy. For example, the expression of Bin1 tumor suppressor or depletion of Hsp70 results in effective induction of caspase-independent apoptosis-like PCD in tumor cells (Elliott et al., 2000; Nylandsted et al., 2000a,b) . Remarkably, adenoviral transfer of antisense Hsp70 cDNA also efficiently eradicates glioblastoma, breast-cancer, and colon-cancer xenografts in mice (J. Nylandsted and M. Jäättelä, unpublished). The ineffective delivery of viral vectors into multiple tumor sites appears to be the major limitation for the usage of this gene therapy in the treatment of human cancer. Thus, clinical applications of this approach require further development of the delivery systems or other means to activate Bin1 or to neutralize the antiapoptotic effect of Hsp70. However, in the case of local inoperable tumors, such as glioblastoma, locoregional gene therapy may prove beneficial.
Even though the signaling pathways regulating alternative PCD are only beginning to emerge, potentially cancer-relevant drugs or drug targets engaging caspase- independent death routines already exist (Figure 6 ). For instance, the topoisomerase inhibitor, camptothecin, induces cathepsin D/B-mediated apoptosis-like PCD in hepatocellular carcinoma cells (Roberts et al., 1999) ; activation of a thrombospondin receptor (CD47) by thrombospondin or agonistic antibodies initiates programmed necrosis in B-cell-chronic lymphoma cells (Mateo et al., 1999) ; antibodies to CD99 trigger a rapid, apoptosis-like PCD in transformed T cells (Pettersen et al., 2001) ; interferons and arsenite initiate a caspase-independent death pathway, possibly mediated by PML (Quignon et al., 1998) ; EB 1089, a synthetic vitamin D analog presently in phase III trials for the treatment of cancer, kills breast-cancer cells in a caspase-independent manner (Mathiasen et al., 1999) ; and treatment of breast-cancer cells with sigma-2 receptor agonists triggers apoptosislike PCD independently of p53 or caspase activity (Crawford and Bowen, 2002) .
Alternative cell death in the nervous system
Caspase-driven neuronal apoptosis strictly following the classic apoptosome pathway is best documented during development of the nervous system (Los et al., 1999) , where many superfluous cells are produced and turned over (Raff, 1992) , and in in vitro cultures of cells derived from developing brain (Mattson, 2000) . Evidence is scarce for adult neurons, and here caspase-dependent mechanisms may yield to alternative death pathways (Johnson et al., 1999) . Notably, a re-evaluation of cell death in caspase knockout mice showed that apoptosis is reduced during development, but cell death in many brain regions proceeds to the same extent in a caspase-independent necrosis-like PCD often characterized by cytoplasmic vacuoles (Oppenheim et al., 2001) . Cell suicide in the adult nervous system has serious implications for the whole organism, since turnover is classically very limited. Thus, a rapid caspase cascade, which is advantageous for efficient elimination of unwanted or rapidly replaceable cells, is dangerous in the developed brain and must be tightly controlled. For instance, neurons can survive cytochrome c release from mitochondria if they do not simultaneously receive a second signal leading to 'competence to die ' (Deshmukh et al., 2000) . Neuronally expressed apoptosis inhibitor proteins (IAP, NAIP) buffer the caspase system, and need to be inactivated before classic apoptosis can be executed (Kaufmann and Hengartner, 2001 ). This buffering capacity may allow for localized caspase activation (Mattson, 2000) (within synapses or neurites, for example) or sequestration of active caspases (Stadelmann et al., 1999) , without a buildup of the death cascade affecting the entire neuron. Stressed neurons might also acquire a temporary resistance that allows them to withstand otherwise lethal insults, such as those by excitotoxins (Hansson et al., 1999) . Such circumstances favor activation of slow, caspase-independent elimination routines, where damaged organelles are digested within a stressed cell, and the chance for rescue and reversibility is maintained until the process is complete (Jellinger and Stadelmann, 2000; Yamamoto et al., 2000; Xue et al., 2001) .
Although some caspase-dependent apoptosis might occur in adult brain (Mattson, 2000) , at least part of PCD in chronic neurodegenerative disease follows alternative mechanisms and results in different morphologies (Miller et al., 1997;  In various human diseases or animal models of them, the dominant form of neuronal disease is, for example, dark cell death in a Huntington's disease model, or vacuolar degeneration in a model of amyotrophic lateral sclerosis (ALS). Selective neurite degeneration occurs independently of caspase activation in different situations, and may eventually lead either to caspase-dependent apoptosis of cell bodies or to nonapoptotic death with irregular chromatin condensation. Excitotoxic death may take many forms and mechanisms depending on the intensity of insult, the age of the animal, and the brain region affected. It often results in mixed apoptotic and necrotic features, including cellular swelling, blebbing, nuclear pyknosis, display of phosphatidylserine, and some autophagic processes, such as uptake of mitochondria into lysosomes. et al., 2001 ) and of infection (Boise and Collins, 2001) . Since these processes can be favored by caspase activation, the classic apoptosis pathways can, in fact, be detrimental to the organism. This may explain the need for extremely tight control of caspase-activation by the cellular energy level (Leist et al., 1997) . The apparent paradox that death-bound ATP-depleted cells are not 'allowed' to activate caspases may then be explained by the fact that such cells would release activated caspases into the extracellular space upon premature lysis (Hentze et al., 2001) . Thus, nonapoptotic death may be not only a passive accidental event, but also, in some cases, a desirable death option for long-lived organisms having to deal with tumors, infections, and other nonlethal tissue insults throughout their life span.
